Supernus stockholders approve merger with Indivior; 48.25M votes for, 235,601 against

SUPERNUS PHARMACEUTICALS, INC.

Proposal 1 (adoption of Merger Agreement) passed: 48,249,532 votes for, 235,601 against, 67,004 abstained, no broker non-votes.
Under the deal, Artemis Merger Sub, Inc. merges into Supernus, which survives as a wholly-owned subsidiary of Indivior Pharmaceuticals Inc.
Proposal 2 (non-binding golden-parachute compensation for named executive officers) passed 32,688,410 for vs 15,847,350 against, 16,377 abstained.
Special Meeting held October 15, 2026; 58,224,143 shares outstanding and entitled to vote as of the September 4, 2026 record date.
Proxy statement for the Special Meeting was filed with the SEC on September 11, 2026; merger closing conditions not detailed in this filing.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.